Literature DB >> 12458387

Expression of functional prolactin and its receptor in human colorectal cancer.

Jan-Michel Otte1, Claudia Otte, Stefanie Beckedorf, Frank Schmitz, Barbara K Vonderhaar, Ulrich R Fölsch, Sievert Kloehn, Karl-Heinz Herzig, Heiner Mönig.   

Abstract

BACKGROUND AND AIMS: Ectopic production of prolactin has been reported for several tumors, and elevated prolactin plasma levels have been detected in colorectal cancer patients. However, the role of prolactin in colorectal cancer remains unclear. We therefore compared expression patterns of prolactin and its receptor in normal and neoplastic colonic mucosa of the same patient with noncancer controls and determined mitogenic effects in vitro.
MATERIALS AND METHODS: mRNA and protein expression was analyzed by semiquantitative RT-PCR and western blotting. Localization of ligand and receptor in tissues was investigated by immunohistochemistry. Mitogenic effects of prolactin on colorectal cancer cell lines (Caco-2, HT-29, LoVo) were assayed by [(3)H]thymidine incorporation.
RESULTS: mRNA expression of prolactin was detected in 13% of normal and 27% of cancer specimens, with the highest levels seen in moderately differentiated tumors. Receptor mRNA was amplified from the majority of normal (96%) and cancer (94%) samples with an overexpression seen in tumor tissues. Protein expression of prolactin was detected in cancer tissues only, with the highest levels seen in moderately differentiated tumors. Receptor protein expression was correlated with the RT-PCR data, showing up to fourfold overexpression in tumor tissues. Staining for both ligand and receptor was observed in epithelial cells. DNA synthesis was significantly stimulated by prolactin in all cell lines reaching 167-197% of unstimulated controls.
CONCLUSION: Expression of prolactin, overexpression of prolactin receptors in colorectal cancers, and mitogenic effects of prolactin suggest a role for this hormone in a subgroup of colorectal cancers, which is presumably mediated by paracrine/autocrine pathways.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12458387     DOI: 10.1007/s00384-002-0414-7

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  8 in total

1.  Prognostic value of prolactin in postoperative colorectal carcinoma.

Authors:  Aman Chauhan; Jacob Kurian; Anjali Kakria; Tanuj Kanchan; Ritesh G Menezes
Journal:  Gastrointest Cancer Res       Date:  2008-09

2.  Opposite association of serum prolactin and survival in patients with colon and rectal carcinomas: influence of preoperative radiotherapy.

Authors:  Marcos Gutiéerrez De La Barrera; Belem Trejo; Pedro Luna-Péerez; Fernándo López-Barrera; Gonzalo Martínez De La Escalera; Carmen Clapp
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

3.  Effects of prolactin on TSC2-null Eker rat cells and in pulmonary lymphangioleiomyomatosis.

Authors:  Yasuhiro Terasaki; Kinnosuke Yahiro; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Mario P Stylianou; Jilly F Evans; Ameae M Walker; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2010-04-22       Impact factor: 21.405

4.  Prolactin signaling enhances colon cancer stemness by modulating Notch signaling in a Jak2-STAT3/ERK manner.

Authors:  Naveen K Neradugomma; Dharmalingam Subramaniam; Ossama W Tawfik; Vincent Goffin; T Rajendra Kumar; Roy A Jensen; Shrikant Anant
Journal:  Carcinogenesis       Date:  2013-11-21       Impact factor: 4.944

5.  Comparative study of tumor markers in patients with colorectal carcinoma before and after chemotherapy.

Authors:  Atreyee Basu; Shashi Seth; Ashok K Chauhan; Nupur Bansal; Kanchan Arora; Anuradha Mahaur
Journal:  Ann Transl Med       Date:  2016-02

6.  ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition.

Authors:  Mark G Anderson; Qian Zhang; Luis E Rodriguez; Claudie M Hecquet; Cherrie K Donawho; Peter J Ansell; Edward B Reilly
Journal:  BMC Cancer       Date:  2021-06-09       Impact factor: 4.430

7.  Engineering synthetic antibody binders for allosteric inhibition of prolactin receptor signaling.

Authors:  Shahir S Rizk; Jean-Louis K Kouadio; Anna Szymborska; Erica M Duguid; Somnath Mukherjee; Jiamao Zheng; Charles V Clevenger; Anthony A Kossiakoff
Journal:  Cell Commun Signal       Date:  2015-01-15       Impact factor: 5.712

8.  Expression of prolactin receptor and prolactin in normal and malignant thyroid: a tissue microarray study.

Authors:  Patrícia Costa; Ana Luísa Catarino; Fernanda Silva; Luís G Sobrinho; Maria João Bugalho
Journal:  Endocr Pathol       Date:  2006       Impact factor: 4.056

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.